Effect of Moderate Hepatic Impairment on the Pharmacokinetics and Pharmacodynamics of Roxadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor

Clinical Drug Investigation

Volumn 36, Issue 9, 2016, Pages 743-751

  Groenendaal van de Meent, Dorien ^a   Adel, Martin den ^a   Noukens, Jan ^b   Rijnders, Sanne ^a   Krebs Brown, Axel ^a   Mateva, Lyudmila ^c   Alexiev, Assen ^c   Schaddelee, Marloes ^a,d  

^a Astellas Pharma Global Development   (Netherlands)

^b Kinesis Pharma BV   (Netherlands)

^c UNIVERSITY HOSPITAL ST IVAN RILSKI   (Bulgaria)

^d ASTELLAS PHARMA INC   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ERYTHROPOIETIN; ROXADUSTAT; FG-4592; GLYCINE; HYPOXIA INDUCIBLE FACTOR 1; ISOQUINOLINE DERIVATIVE; PROLYL HYDROXYLASE INHIBITOR;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BODY MASS; CHILD PUGH SCORE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; LEUKOCYTE COUNT; LIVER CIRRHOSIS; LIVER FUNCTION; MALE; MAXIMUM PLASMA CONCENTRATION; MODERATE HEPATIC IMPAIRMENT; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PHARMACODYNAMIC PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; ADOLESCENT; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; HALF LIFE TIME; LIVER DISEASE; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AREA UNDER CURVE; ERYTHROPOIETIN; FEMALE; GLYCINE; HALF-LIFE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; ISOQUINOLINES; LIVER CIRRHOSIS; LIVER DISEASES; MALE; MIDDLE AGED; PROLYL-HYDROXYLASE INHIBITORS; YOUNG ADULT;

EID: 84976345140     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-016-0422-y     Document Type: Article

References (15)

1. Coresh J, Selvin E, Stevens LA, Manzi J, Kusek JW, Eggers P, et al. Prevalence of chronic kidney disease in the United States. JAMA. 2007;298:2038–47.
2. KDIGO. Clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1–150.
3. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, et al. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003;139:137–47.
4. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health. 2008;8:117.
5. Babitt JL, Lin HY. Mechanisms of anemia in CKD. J Am Soc Nephrol. 2012;23:1631–4.
6. Ebben JP, Gilbertson DT, Foley RN, Collins AJ. Hemoglobin level variability: associations with comorbidity, intercurrent events, and hospitalizations. Clin J Am Soc Nephrol. 2006;1:1205–10.
7. Slotki I. Intravenous iron supplementation in the anaemia of renal and cardiac failure: a double-edged sword? Nephrol Dial Transplant. 2005;20(Suppl 7):vii16–23.
8. Macdougall IC, Casadevall N, Locatelli F, Combe C, London GM, Di PS, et al. Incidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS). Nephrol Dial Transplant. 2015;30:451–60.
9. Krapf R, Hulter HN. Arterial hypertension induced by erythropoietin and erythropoiesis-stimulating agents (ESA). Clin J Am Soc Nephrol. 2009;4:470–80.
10. Zhu X, Perazella MA. Nonhematologic complications of erythropoietin therapy. Semin Dial. 2006;19:279–84.
11. Scornik JC, Bromberg JS, Norman DJ, Bhanderi M, Gitlin M, Petersen J. An update on the impact of pre-transplant transfusions and allosensitization on time to renal transplant and on allograft survival. BMC Nephrol. 2013;14:217.
12. Besarab A, Provenzano R, Fishbane S, Sun CH, Belo S, Neff TB, et al. FG-4592 Oral hypoxia-Inducible factor prolyl hydroxylase inhibitor corrects anemia in nondialysis CKD patients without IV iron. J Am Soc Nephrol. 2011;22:196A.
13. Jelkmann W. Physiology and pharmacology of erythropoietin. Transfus Med Hemother. 2013;40:302–9.
14. US Food and Drug Administration. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2003. Available at: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072123.pdf. Accessed 13 June 2016.
15. Committee for Medicinal Products for Human Use. Guideline on the evaluation of the pharmacokinetics of medicinal products in patients with impaired hepatic function. EMEA 2005. CPMP/EWP/2339/02. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003122.pdf. Accessed 13 June 2016.